Suggested remit: To appraise the clinical and cost effectiveness of dapagliflozin within its marketing authorisation for treating chronic kidney disease.
Status In progress
Process STA 2018
ID number 3866

Provisional Schedule

Committee meeting 14 October 2021
Expected publication 05 January 2022

Project Team

Project lead Kate Moore

Email enquiries

Evidence Review Group / Assessment Group School of Health and Related Research (ScHARR), University of Sheffield


Companies sponsors AstraZeneca (dapagliflozin)
Others Department of Health and Social Care
  NHS England
  NHS Greenwich CCG
  NHS Lincolnshire East CCG
  Welsh Government
Patient carer groups Kidney Care UK
  Kidney Research UK
  National Kidney Federation
  Network of Sikh Organisations
  Polycystic Kidney Disease Charity
  South Asian Health Foundation
  Specialised Healthcare Alliance
Professional groups Association of Anaesthetists of Great Britain & Ireland
  Association of Renal Technologists
  Association of Surgeons of Great Britain and Ireland
  British Association of Urological Nurses
  British Association of Urological Surgeons
  British Geriatrics Society
  British Renal Society
  British Transplantation Society
  NHS Blood and Transplant
  Primary Care Cardiovascular Society
  Primary Care Diabetes Society
  Renal Association
  Royal College of Anaesthetists
  Royal College of General Practitioners
  Royal College of Nursing
  Royal College of Pathologists
  Royal College of Physicians
  Royal College of Surgeons of England
  Royal Pharmaceutical Society
  Royal Society of Medicine
  Society for DGH Nephrologists
  UK Clinical Pharmacy Association
  UK Renal Pharmacy Group


Associated public health groups Public Health England
  Public Health Wales
Comparator companies Accord (captopril, enalapril, eplerenone, fosinopril, irbesartan, lisinopril, losartan, olmesartan, perindopril, ramipril, telmisartan, trandolapril, valsartan)
  Aspire (eplerenone)
  AstraZeneca (lisinopril)
  Aurobindo pharma (candesartan, carvedilol, enalapril, fosinopril irbesartan, lisinopril, losartan, olmesartan, perindopril, ramipril, valsartan)
  Boehringer Ingelheim (telmisartan)
  Bristol laboratories (lisinopril)
  Brown and Burk (irbesartan, lisinopril, losartan, ramipril)
  Consilient health (candesartan, eplerenone, irbesartan, losartan, perindopril, telmisartan)
  Daiichi Sankyo (olmesartan)
  Dexcel pharma (enalapril, losartan, valsartan)
  Glenmark pharma (olmesartan, perindopril, telmisartan)
  Lupin Healthcare (irbesartan)
  Martindale pharma (captopril)
  Novartis (valsartan)
  Organon (enalapril, losartan)
  Pfizer (quinapril)
  Sandoz (candesartan, losartan, ramipril, telmisartan)
  Sanofi (irbesartan, ramipril)
  Servier laboratories (perindopril)
  Takeda (azilsartan, candesartan)
  Ten pharma (captopril)
  Thame laboratories (captopril)
  Thornton & Ross (olmesartan)
  Tillomed laboratories (eplerenone, perindopril)
  Viatris. (candesartan, enalapril, eplerenone, eprosartan, fosinopril lisinopril, losartan, olmesartan, perindopril, trandolapril, valsartan)
  Zentiva (eplerenone, irbesartan, ramipril)
General commentators All Wales Therapeutic and Toxicology Centre
  Allied Health Professionals Federation
  Association of Renal Industries
  Board of Community Health Councils in Wales
  British National Formulary
  Care Quality Commission
  Department of Health, Social Services and Public Safety for Northern Ireland
  Healthcare Improvement Scotland
  Medicines and Healthcare Products Regulatory Agency
  National Association of Primary Care
  National Pharmacy Association
  NHS Alliance
  NHS Confederation
  Scottish Medicines Consortium
  Welsh Health Specialised Services Committee
  Welsh Kidney Patients Association
Relevant research groups Centre for Kidney Research and Innovation
  Cochrane Kidney and Transplant
  Genomics England
  Kidney Research UK
  MRC Clinical Trials Unit
  National Institute for Health Research
  Society for Research in Rehabilitation
  Wellcome Trust


Key events during the development of the guidance:

Date Update
30 March 2021 Invitation to participate
30 March 2021 In progress. Invitation to participate issued
03 February 2021 - 03 March 2021 Consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentators

For further information on how we develop guidance, please see our page about NICE technology appraisal guidance